Asherman's syndrome secondary prevention

Asherman's syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Asherman's syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Asherman's syndrome secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Asherman's syndrome secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Asherman's syndrome secondary prevention
CDC on Asherman's syndrome secondary prevention
Asherman's syndrome secondary prevention in the news
Blogs on Asherman's syndrome secondary prevention
Directions to Hospitals Treating Asherman's syndrome
Risk calculators and risk factors for Asherman's syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Saud Khan M.D.

Overview

Reevaluation one to two weeks postoperatively after hysteroscopy to remove adhesions may allow earlier identification of recurrent scar tissue while immature and small in size, allowing resection before these adhesions worsen.

References

Template:WikiDoc Sources